Sort
48,018 grants matching “immunotherapy”
Mechanisms of impaired T-cell mechanosensing of melanoma antigens
$780,284Cheng Zhu · Georgia Institute Of Technology · U01 · FY2017 · CA
Pathogenesis and Treatment of Anaphylaxis
$780,272Dean D Metcalfe · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Fibroblast Heterogeneity in Pancreatic Cancer
$780,205David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2023 · CA
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
$780,148Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2024 · CA
Clinical Fellowship Training Program
$780,135Peter Pinto · Division Of Basic Sciences - Nci · ZIE · FY2018 · CA
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
$780,080Roland K Strong · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
Signal Transduction Events and the Regulation of Cell Growth
$780,073Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2018 · CA
New therapeutics for Shiga toxin-E. coli disease.
$780,015Fumiko Obata · University Of Maryland Baltimore · U01 · FY2010 · AI
Engineering T cells to Promote Islet Transplant
$780,000James L Riley · University Of Pennsylvania · R01 · FY2022 · DK
Targeting alternative splicing for TCR discovery in small cell carcinomas
$779,998Owen N Witte · University Of California Los Angeles · U01 · FY2020 · CA
Targeting alternative splicing for TCR discovery in small cell carcinomas
$779,998Owen N Witte · University Of California Los Angeles · U01 · FY2021 · CA
Targeting alternative splicing for TCR discovery in small cell carcinomas
$779,998Owen N Witte · University Of California Los Angeles · U01 · FY2019 · CA
Targeting alternative splicing for TCR discovery in small cell carcinomas
$779,998Owen N Witte · University Of California Los Angeles · U01 · FY2022 · CA
Targeting alternative splicing for TCR discovery in small cell carcinomas
$779,998Owen N Witte · University Of California Los Angeles · U01 · FY2018 · CA
Fibroblast Heterogeneity in Pancreatic Cancer
$779,963David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2022 · CA
Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer
$779,894Lorenzo Galluzzi · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA
Determinants of oral anaphylaxis to food
$779,775Adam Williams · Northwestern University At Chicago · R01 · FY2025 · AI
Developing broad-spectrum therapeutics against C. difficile toxins
$779,693Rongsheng Jin · University Of California-Irvine · R01 · FY2022 · AI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$779,653Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Role of Disease-Associated Microglia in Alzheimer's disease
$779,590Kim Green · University Of California-Irvine · R01 · FY2024 · AG
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy
$779,005Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2022 · DE
Southern Nevada Cancer Research Foundation--CCOP
$778,993Southern Nevada Cancer Research Fdn · U10 · FY2002 · CA
Fcgamma receptor-mediated suppression of immunodeficiency virus replication
$778,850David T Evans · University Of Wisconsin-Madison · R01 · FY2015 · AI
Engineered Immune Cells for T1D
$778,837Everett Meyer · Stanford University · R01 · FY2023 · DK
PEDIATRICS AIDS CLINICAL TRIALS GROUP
$778,575Columbia University Health Sciences · U01 · FY2004 · AI